Search Results

Pharmacokinetic Modeling and Simulation of Gastrointestinal Transit Effects on Plasma Concentrations of Drugs from Mixed Immediate-Release and Enteric-Coated Pellet Formulations

Authors: Watanalumlerd, Prapoch; Christensen, J. Mark; Ayres, James W.

Source: Pharmaceutical Development and Technology, Volume 12, Number 2, March 2007 , pp. 193-202(10)

Publisher: Informa Healthcare

Treatment of attention deficit hyperactivity disorder in adults

Authors: Greenfield, Brain; Hechman, Lily

Source: Expert Review of Neurotherapeutics, Volume 5, Number 1, January 2007 , pp. 107-121(15)

Publisher: Expert Reviews

Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release

Authors: Ermer, James C.; Shojaei, Amir; Pennick, Michael; Anderson, Colleen S.; Silverberg, Arthur; Youcha, Sharon H.

Source: Current Medical Research and Opinion, Volume 23, Number 5, May 2007 , pp. 1067-1075(9)

Publisher: Informa Healthcare

Extended-release (OROS) methylphenidate is more effective than SLI 381 [Adderall XR] for improving driving performance in adolescents with ADHD

Source: Inpharma, Volume 1, Number 1560, 2006-10-21 , pp. 12-12(1)

Publisher: Adis International

Mixed amphetamine salts extended release: a clinical review of its use in the treatment of attention-deficit hyperactivity disorder

Author: Grcevich, Stephen

Source: Future Neurology, Volume 1, Number 5, September 2006 , pp. 525-534(10)

Publisher: Future Medicine

Long-term Adderall XR demands attention in paediatric ADHD

Source: Inpharma, Volume 1, Number 1500, 2005-08-13 , pp. 14-14(1)

Publisher: Adis International

Adderall XR allowed back on the Canadian market

Source: Reactions, Volume 1, Number 1067, 2005-09-03 , pp. 2-2(1)

Publisher: Adis International

Revised labelling for Adderall XR in Canada

Source: Reactions, Volume 1, Number 1068, 2005-09-10 , pp. 2-2(1)

Publisher: Adis International

Revised labelling for Adderall XR in Canada

Source: Inpharma, Volume 1, Number 1504, 2005-09-10 , pp. 20-20(1)

Publisher: Adis International

Adderall XR allowed back on the Canadian market

Source: Inpharma, Volume 1, Number 1503, 2005-09-03 , pp. 21-21(1)

Publisher: Adis International

Paying Close Attention to the ADHD Market: Shire Pharmaceuticals Planning ‘One-Stop Shop’

Author: Adis International Limited,

Source: Pharmaceutical & Diagnostic Innovation, Volume 3, Number 6, 2005 , pp. 6-9(4)

Publisher: Adis International

Safety, efficacy and extended duration of action of mixed amphetamine salts extended- release capsules for the treatment of ADHD

Author: Weisler, Richard H

Source: Expert Opinion on Pharmacotherapy, Volume 6, Number 6, 1 June 2005 , pp. 1003-1017(15)

Publisher: Informa Healthcare

Adderall XR: long acting stimulant for single daily dosing

Authors: Sallee, Floyd R; Smirnoff, Alexander V

Source: Expert Review of Neurotherapeutics, Volume 4, Number 6, November 2004 , pp. 927-934(8)

Publisher: Expert Reviews

Methodological Issues in the Assessment of Medication Effects in Children Diagnosed with Attention Deficit Hyperactivity Disorder (ADHD)

Author: Scott H. Kollins

Source: Journal of Behavioral Education, Volume 13, Number 4, December 2004 , pp. 247-266(20)

Publisher: Springer

SLI-381 (Adderall XR^®)

Authors: McKeage K.; Scott L.J.

Source: CNS Drugs, Volume 17, Number 9, 2003 , pp. 669-675(7)

Publisher: Adis International

SLI-381 (Adderall XR®): A Viewpoint by Charlotte Johnston

Author: Johnston C.

Source: CNS Drugs, Volume 17, Number 9, 2003 , pp. 676-677(2)

Publisher: Adis International

SLI-381 (Adderall XR®): A Viewpoint by Paul J. Ambrosini

Author: Ambrosini P.J.

Source: CNS Drugs, Volume 17, Number 9, 2003 , pp. 676-677(2)

Publisher: Adis International

Reply to comments by Gonzalez et al. on the CONCERTA, Adderall XR Food Evaluation (CAFE) Study

Authors: Auiler, Joanna F.; Lynch, Joseph M.; Gelotte, Cathy K.

Source: Current Medical Research and Opinion, Volume 19, Number 1, 1 February 2003 , pp. 64-65(2)

Publisher: Informa Healthcare

Effect of Food on Early Drug Exposure from Extended-Release Stimulants: Results from the Concerta®, Adderall XR™ Food Evaluation (CAFÉ) Study

Authors: Auiler J. F.; Liu K.; Lynch J. M.; Gelotte C. K.

Source: Current Medical Research and Opinion, Volume 18, Number 5, 1 July 2002 , pp. 311-316(6)

Publisher: Informa Healthcare

SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder

Author: Grcevich S.

Source: Expert Opinion on Investigational Drugs, Volume 10, Number 11, 1 November 2001 , pp. 2003-2011(9)

Publisher: Informa Healthcare